Kezar investors get cash now and future drug upside in Aurinia deal Aurinia plans to start its tender offer by Apr. 13, with closing expected in Q2 2026. Tang Capital, which owns about 9%, agreed to support the deal.

#KZR #AUPH Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

www.stocktitan.net/news/KZR/aurinia-pharmac...

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress Aurinia Pharmaceuticals (NASDAQ: AUPH) reported 2025 results: total revenue $283.1M (+20%) and LUPKYNIS net product sales $271.3M (+25%). Net income was $287.2M driven by a $173.0M income tax benefit from releasing a valuation allowance. Cash and investments were $398.0M; the company repurchased 12.2M shares for $98.2M. For 2026 Aurinia guides total revenue $315M–$325M and LUPKYNIS sales $305M–$315M. The company plans additional clinical starts for aritinercept in H1 2026.

#AUPH Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

www.stocktitan.net/news/AUPH/aurinia-pharma...

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress Aurinia Pharmaceuticals (NASDAQ: AUPH) reported results for the three and nine months ended September 30, 2025, showing continued commercial momentum for LUPKYNIS and progress on clinical programs.Key figures: Q3 total revenue $73.5M (+8% YoY); 9M revenue $205.9M (+17% YoY). Q3 LUPKYNIS net product sales $70.6M (+27% YoY); 9M LUPKYNIS sales $197.2M (+24% YoY). Net income was $31.6M Q3 and $76.4M 9M; diluted EPS $0.23 Q3 and $0.55 9M. Operating cash flow was $44.5M Q3 and $90.0M 9M.The company raised 2025 guidance to $275–$280M total revenue and $265–$270M net product sales, repurchased 12.2M shares for $98.2M, and reported cash, equivalents and investments of $351.8M. Aurinia also noted positive Phase 1 aritinercept results and plans to start clinical studies in two autoimmune diseases by year-end.

#AUPH Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

www.stocktitan.net/news/AUPH/aurinia-pharma...

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PROP 583.0x
2. #PSEC 285.0x
3. #IRT 138.8x
4. #AUPH 60.2x
5. #SMG 45.0x

#OptionFlow #OptionsTrading #Trading

Aurinia (AUPH) Q2 Revenue Jumps 22% | The Motley Fool

#AUPH #33eb6148-a309-43df-8e1c-f727058fe994 #data-news

Origin | Interest | Match

Aurinia Smashes Q2 Expectations: Revenue Up 22%, LUPKYNIS Sales Soar, 2025 Guidance Raised Q2 revenue hits $70M as LUPKYNIS sales surge 21%. Company raises full-year guidance and expands $150M share buyback program. See full financial details.

#AUPH Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

www.stocktitan.net/news/AUPH/aurinia-pharma...

Aurinia Pharmaceuticals Q2 2025 Earnings Call: Key Details for Investors Before Market Open July 31 Aurinia sets Q2 earnings call for July 31 at 8:30 AM ET, featuring management insights and operational updates. Join the discussion live.

#AUPH Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

www.stocktitan.net/news/AUPH/aurinia-pharma...

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) Aurinia Pharmaceuticals (NASDAQ: AUPH) announced positive results from its Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), a dual inhibitor targeting B cell-activating factor (BAFF) and proliferation-inducing ligand (APRIL). The study evaluated six different doses (5mg to 300mg) and placebo in 61 healthy subjects.The trial demonstrated that aritinercept was well-tolerated across all dose levels, with no treatment-related Grade ≥3 adverse events, serious adverse events, or discontinuations. Key adverse events included injection site reactions (24% aritinercept vs. 13% placebo), headache (11% vs. 7%), and upper respiratory tract infection (7% vs. 0%).The drug showed significant pharmacodynamic effects, with mean reductions from baseline to Day 28 of up to 48% in immunoglobulin A (IgA), 55% in immunoglobulin M (IgM), and 20% in immunoglobulin G (IgG). Based on these results, Aurinia plans to initiate clinical studies in at least two autoimmune diseases in the second half of 2025.

#AUPH Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

www.stocktitan.net/news/AUPH/aurinia-announ...

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis Aurinia Pharmaceuticals (NASDAQ: AUPH) presented new post-hoc analysis of its Phase 3 AURORA 1 study at LUPUS 2025, demonstrating superior efficacy of LUPKYNIS-based triple immunosuppressive therapy in lupus nephritis patients. The analysis showed that 60.9% of patients receiving LUPKYNIS with MMF and low-dose glucocorticoids achieved urine protein creatine ratio (UPCR) of ≤0.4 g/g, compared to 37.1% in the control group. Additional analysis revealed distinct lipidomic profiles in patients achieving ultra-low UPCR, suggesting potential cardiovascular benefits. The study found significant improvements in total and LDL cholesterol levels in the LUPKYNIS group. Importantly, adverse event rates remained comparable between treatment groups, supporting LUPKYNIS's safety profile. The findings emphasize LUPKYNIS's crucial role in achieving lower proteinuria targets and improving long-term kidney outcomes for lupus nephritis patients.

#AUPH New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

www.stocktitan.net/news/AUPH/new-aurora-1-a...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish moving average convergence divergence crossovers, Tue May 13th - #ZTEK #VTYX #TALK #SATL #RLAY #PHVS #OTLY #LWAY #KPTI #INZY #IIIV #HITI #GAIA #ERAS #DOYU #AUPH #UVV #LTC #GRDN #CGAU - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 Aurinia Pharmaceuticals (NASDAQ: AUPH) reported strong Q1 2025 financial results, with total revenue reaching $62.5 million, up 24% year-over-year. LUPKYNIS, their FDA-approved oral therapy for lupus nephritis, generated net product sales of $60.0 million, a 25% increase from 2024. The company achieved a significant turnaround with net income of $23.3 million, compared to a loss of $10.7 million in Q1 2024. Operating cash flow improved to $1.3 million, versus -$18.6 million last year. Aurinia maintained a strong cash position of $312.9 million and repurchased 5.8 million shares for $47.4 million. The company reaffirmed its 2025 guidance with total revenue of $250-260 million and net product sales of $240-250 million. Additionally, Aurinia expects to report initial results from its Phase 1 study of AUR200 later this quarter.

#AUPH Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

www.stocktitan.net/news/AUPH/aurinia-pharma...

Aurinia Pharmaceuticals Announces Q1 2025 Earnings Call: Key Details for Investors Join Aurinia's Q1 2025 earnings call on May 12 at 8:30 AM ET. Management to discuss financial results and provide business updates. Get access details.

#AUPH Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

www.stocktitan.net/news/AUPH/aurinia-pharma...

From $78M Loss to Profitable: How Aurinia's LUPKYNIS Drug Transformed Its Financials Aurinia reports $235.1M in 2024 revenue and $5.8M net income, a dramatic turnaround from 2023's $78M loss, with strong 2025 guidance and pipeline progress.

#AUPH Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

www.stocktitan.net/news/AUPH/aurinia-pharma...

When Will Aurinia Report Q4 Earnings? Key Date and Details for Investors Aurinia sets earnings call for February 27, 8:30 AM ET. Management to discuss Q4 and full-year 2024 performance, plus strategic updates.

#AUPH Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

www.stocktitan.net/news/AUPH/aurinia-pharma...

#AUPH Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

www.stocktitan.net/news/AUPH/aurinia-commen...

BREAKING NEWS: ( NASDAQ: #AUPH ) Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

#StockMarket #News

News; ( NASDAQ: #AUPH ) Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development

#StockMarket #News

JUST IN: ( NASDAQ: #AUPH ) Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

#StockMarket #News

Just In: ( NASDAQ: #AUPH ) (AUPH) Technical Pivots with Risk Controls

#StockMarket #News

News; ( NASDAQ: #AUPH ) Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

#StockMarket #News